Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation

Stockholm, Sweden - September 23, 2010 - Swedish Orphan Biovitrum (STO:SOBI)
today announced that the European Commission has granted orphan drug designation
to its long-lasting, fully-recombinant Factor FVIII Fc fusion protein
(rFVIIIFc), which is partnered with Biogen Idec (NASDAQ: BIIB).  It was recently
announced that the companies plan to advance the rFVIIIFc program into a
registrational clinical trial in patients with severe hemophilia A.

Treatment  of  severe  hemophilia  A  requires  frequent  infusions,  creating a
significant  burden for individuals  with the condition.  The rFVIIIFc molecule,
which  is  based  on  Biogen  Idec's  novel  and proprietary monomeric Fc-fusion
technology,  is being investigated for the  potential to prolong protection from
bleeding  and  reduce  the  frequency  of  injections  for  both prophylaxis and
on-demand therapy in hemophilia A.

"The   orphan   drug   designation  is  very  valuable  for  our  promising  and
high-opportunity  rFVIIIFc  project  as  it  allows European Medicine Agency fee
reduction,  protocol scientific  advice, and  gives market  exclusivity once the
product is approved and receives orphan status. This will help us in our efforts
to  bring this innovative  rFVIIIFc product to  hemophilia patients," said Peter
Edman, Ph.D., Chief Scientific Officer of Swedish Orphan Biovitrum.

About Hemophilia A
Hemophilia  A is a rare,  inherited disorder in which  the ability of a person's
blood  to clot is impaired. Hemophilia A occurs in about 1 in 10,000 male births
annually  and  is  caused  by  having  substantially  reduced  or no factor VIII
protein,  which is  needed for  normal blood  clotting. People with hemophilia A
therefore  need injections of factor VIII to restore the coagulation process and
prevent  frequent bleeds that  could otherwise lead  to pain, irreversible joint
damage  and life-threatening  hemorrhages. Prophylaxis  treatment with infusions
three  times per week or  every second day to  maintain a sufficient circulating
level  of coagulation factor  is being increasingly  used, and long-term studies
demonstrate  that  such  regimens  increase  the  patient's  life expectancy and
greatly  reduce if  not eliminate  progressive joint  deterioration. The current
global market for recombinant Factor VIII products exceeds 4 BUSD annually.

About Swedish Orphan Biovitrum
Swedish  Orphan  Biovitrum  is  a  Swedish  based niche specialty pharmaceutical
company  with  an  international  market  presence.  The  company  is focused on
providing  and developing  specialist pharmaceuticals  for rare disease patients
with  high medical needs.  The portfolio consists  of about 60 marketed products
and  an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia,   inflammation/autoimmune   diseases,   fat   malabsorption,  cancer
supportive care and inherited metabolic disorders.  Swedish Orphan Biovitrum had
pro-forma  revenues 2009e of  about 2 BSEK  and approximately 500 employees. The
head  office is located in Sweden and the  share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. For more information please visitwww.sobi.com.



For more information please contact: Swedish Orphan Biovitrum AB (publ):


Peter Edman, CSO
Phone. +46 8 697 21 77
E-mail:[email protected]

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mail:[email protected]



Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on September 23, 2010 at 8:30 a.m. CET.